SRPT logo

Sarepta Therapeutics, Inc. (SRPT) Cash From Operations

Annual CFO:

-$205.79M+$295.21M(+58.92%)
December 31, 2024

Summary

  • As of today, SRPT annual cash from operations is -$205.79 million, with the most recent change of +$295.21 million (+58.92%) on December 31, 2024.
  • During the last 3 years, SRPT annual cash from operations has risen by +$237.38 million (+53.56%).
  • SRPT annual cash from operations is now -291.49% below its all-time high of $107.47 million, reached on December 31, 2020.

Performance

SRPT Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSRPTcash flow metrics

Quarterly CFO:

-$27.37M-$288.71M(-110.47%)
September 30, 2025

Summary

  • As of today, SRPT quarterly cash from operations is -$27.37 million, with the most recent change of -$288.71 million (-110.47%) on September 30, 2025.
  • Over the past year, SRPT quarterly cash from operations has increased by +$43.33 million (+61.28%).
  • SRPT quarterly cash from operations is now -104.36% below its all-time high of $627.79 million, reached on March 31, 2020.

Performance

SRPT Quarterly Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSRPTcash flow metrics

TTM CFO:

-$257.43M+$43.33M(+14.41%)
September 30, 2025

Summary

  • As of today, SRPT TTM cash from operations is -$257.43 million, with the most recent change of +$43.33 million (+14.41%) on September 30, 2025.
  • Over the past year, SRPT TTM cash from operations has increased by +$95.06 million (+26.97%).
  • SRPT TTM cash from operations is now -182.19% below its all-time high of $313.22 million, reached on March 31, 2020.

Performance

SRPT TTM Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSRPTcash flow metrics

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

SRPT Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+58.9%+61.3%+27.0%
3Y3 Years+53.6%+57.9%+1.9%
5Y5 Years+54.9%+88.5%-326.1%

SRPT Cash From Operations Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+58.9%-110.5%+95.3%-25.1%+53.0%
5Y5-Year-291.5%+58.9%-110.5%+95.3%-326.1%+63.3%
All-TimeAll-Time-291.5%+58.9%-104.4%+95.3%-182.2%+63.3%

SRPT Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2025
-
-$27.37M(-110.5%)
-$257.43M(+14.4%)
Jun 2025
-
$261.34M(+144.8%)
-$300.75M(+45.0%)
Mar 2025
-
-$583.44M(-733.9%)
-$547.15M(-165.9%)
Dec 2024
-$205.79M(+58.9%)
$92.05M(+230.2%)
-$205.79M(+41.6%)
Sep 2024
-
-$70.70M(-573.2%)
-$352.49M(+11.1%)
Jun 2024
-
$14.94M(+106.2%)
-$396.50M(+25.7%)
Mar 2024
-
-$242.08M(-342.9%)
-$533.67M(-6.5%)
Dec 2023
-$500.99M(-54.0%)
-$54.66M(+52.4%)
-$500.99M(+7.0%)
Sep 2023
-
-$114.71M(+6.2%)
-$538.73M(-10.2%)
Jun 2023
-
-$122.23M(+41.6%)
-$488.99M(-12.8%)
Mar 2023
-
-$209.40M(-126.6%)
-$433.57M(-33.3%)
Dec 2022
-$325.35M(+26.6%)
-$92.39M(-42.2%)
-$325.35M(-24.0%)
Sep 2022
-
-$64.96M(+2.8%)
-$262.28M(+18.5%)
Jun 2022
-
-$66.81M(+34.0%)
-$321.64M(+11.6%)
Mar 2022
-
-$101.17M(-245.0%)
-$363.98M(+17.9%)
Dec 2021
-$443.17M(-512.4%)
-$29.33M(+76.4%)
-$443.17M(+24.7%)
Sep 2021
-
-$124.33M(-13.9%)
-$588.38M(+16.2%)
Jun 2021
-
-$109.15M(+39.5%)
-$702.24M(-0.2%)
Mar 2021
-
-$180.37M(-3.3%)
-$700.70M(-752.0%)
Dec 2020
$107.47M(+123.5%)
-$174.53M(+26.7%)
$107.47M(-5.6%)
Sep 2020
-
-$238.19M(-121.4%)
$113.87M(-60.0%)
Jun 2020
-
-$107.60M(-117.1%)
$284.62M(-9.1%)
Mar 2020
-
$627.79M(+473.4%)
$313.22M(+168.0%)
Dec 2019
-$456.46M(-17.4%)
-$168.13M(-149.3%)
-$460.80M(-11.0%)
Sep 2019
-
-$67.43M(+14.6%)
-$415.09M(+10.0%)
Jun 2019
-
-$79.00M(+46.0%)
-$460.98M(+7.7%)
Mar 2019
-
-$146.23M(-19.5%)
-$499.23M(-28.4%)
Dec 2018
-$388.66M(-67.5%)
-$122.42M(-8.0%)
-$388.66M(-30.7%)
Sep 2018
-
-$113.32M(+3.4%)
-$297.30M(-22.9%)
Jun 2018
-
-$117.25M(-228.7%)
-$241.88M(-15.3%)
Mar 2018
-
-$35.67M(-14.8%)
-$209.78M(+9.6%)
Dec 2017
-$232.00M(+5.6%)
-$31.06M(+46.4%)
-$232.00M(+17.8%)
Sep 2017
-
-$57.90M(+32.0%)
-$282.17M(+1.0%)
Jun 2017
-
-$85.15M(-47.1%)
-$284.88M(-17.2%)
Mar 2017
-
-$57.89M(+28.7%)
-$243.02M(+1.1%)
Dec 2016
-$245.82M(-64.5%)
-$81.23M(-34.0%)
-$245.82M(-25.5%)
Sep 2016
-
-$60.62M(-40.0%)
-$195.86M(-7.9%)
Jun 2016
-
-$43.28M(+28.7%)
-$181.56M(-8.8%)
Mar 2016
-
-$60.69M(-94.1%)
-$166.81M(-11.6%)
Dec 2015
-$149.47M(-16.3%)
-$31.27M(+32.5%)
-$149.47M(-4.1%)
Sep 2015
-
-$46.31M(-62.3%)
-$143.64M(-8.3%)
Jun 2015
-
-$28.53M(+34.2%)
-$132.65M(+7.6%)
Mar 2015
-
-$43.35M(-70.3%)
-$143.62M(-11.7%)
Dec 2014
-$128.54M(-98.7%)
-$25.45M(+27.9%)
-$128.54M(-6.3%)
Sep 2014
-
-$35.32M(+10.6%)
-$120.91M(-14.6%)
Jun 2014
-
-$39.50M(-39.8%)
-$105.47M(-35.3%)
Mar 2014
-
-$28.27M(-58.6%)
-$77.97M(-20.5%)
Dec 2013
-$64.69M(-117.9%)
-$17.82M(+10.3%)
-$64.69M(-19.7%)
Sep 2013
-
-$19.88M(-65.6%)
-$54.03M(-28.8%)
Jun 2013
-
-$12.00M(+19.9%)
-$41.96M(-17.7%)
Mar 2013
-
-$14.99M(-109.5%)
-$35.64M(-20.0%)
Dec 2012
-$29.69M(-25.4%)
-$7.16M(+8.3%)
-$29.69M(-5.4%)
Sep 2012
-
-$7.80M(-37.4%)
-$28.18M(-1.0%)
Jun 2012
-
-$5.68M(+37.2%)
-$27.90M(-23.1%)
Mar 2012
-
-$9.05M(-60.2%)
-$22.66M(+4.3%)
Dec 2011
-$23.68M
-$5.65M(+24.9%)
-$23.68M(-18.9%)
Sep 2011
-
-$7.52M(-1602.0%)
-$19.92M(-31.3%)
Jun 2011
-
-$442.00K(+95.6%)
-$15.17M(+20.0%)
DateAnnualQuarterlyTTM
Mar 2011
-
-$10.07M(-433.2%)
-$18.96M(-24.7%)
Dec 2010
-$15.21M(-72.8%)
-$1.89M(+31.9%)
-$15.21M(-5.8%)
Sep 2010
-
-$2.77M(+34.5%)
-$14.38M(-7.8%)
Jun 2010
-
-$4.24M(+32.9%)
-$13.34M(+1.1%)
Mar 2010
-
-$6.31M(-497.2%)
-$13.50M(-53.4%)
Dec 2009
-$8.80M(+28.7%)
-$1.06M(+39.2%)
-$8.80M(+13.9%)
Sep 2009
-
-$1.74M(+60.4%)
-$10.22M(+19.6%)
Jun 2009
-
-$4.39M(-171.8%)
-$12.71M(-33.4%)
Mar 2009
-
-$1.61M(+34.7%)
-$9.53M(+22.8%)
Dec 2008
-$12.34M(+50.0%)
-$2.47M(+41.5%)
-$12.34M(+28.2%)
Sep 2008
-
-$4.23M(-249.1%)
-$17.19M(+2.2%)
Jun 2008
-
-$1.21M(+72.6%)
-$17.58M(+25.5%)
Mar 2008
-
-$4.43M(+39.6%)
-$23.61M(+4.3%)
Dec 2007
-$24.68M(-19.7%)
-$7.33M(-58.6%)
-$24.68M(-9.7%)
Sep 2007
-
-$4.62M(+36.2%)
-$22.49M(+4.1%)
Jun 2007
-
-$7.24M(-31.7%)
-$23.45M(-12.6%)
Mar 2007
-
-$5.49M(-6.8%)
-$20.82M(-1.0%)
Dec 2006
-$20.61M(-40.5%)
-$5.15M(+7.6%)
-$20.61M(-1.9%)
Sep 2006
-
-$5.57M(-20.9%)
-$20.24M(-30.6%)
Jun 2006
-
-$4.61M(+12.8%)
-$15.50M(+0.5%)
Mar 2006
-
-$5.29M(-10.9%)
-$15.58M(-6.2%)
Dec 2005
-$14.67M(+38.3%)
-$4.77M(-475.4%)
-$14.67M(-10.0%)
Sep 2005
-
-$828.90K(+82.3%)
-$13.33M(+26.5%)
Jun 2005
-
-$4.69M(-7.1%)
-$18.15M(+11.2%)
Mar 2005
-
-$4.38M(-27.6%)
-$20.43M(+14.1%)
Dec 2004
-$23.78M(-36.0%)
-$3.43M(+39.2%)
-$23.78M(+4.8%)
Sep 2004
-
-$5.65M(+19.0%)
-$24.98M(-9.6%)
Jun 2004
-
-$6.97M(+9.8%)
-$22.79M(-20.8%)
Mar 2004
-
-$7.73M(-67.0%)
-$18.86M(-7.9%)
Dec 2003
-$17.48M(+13.7%)
-$4.63M(-33.8%)
-$17.48M(-6.1%)
Sep 2003
-
-$3.46M(-13.6%)
-$16.47M(+2.8%)
Jun 2003
-
-$3.04M(+52.0%)
-$16.94M(+23.5%)
Mar 2003
-
-$6.35M(-75.4%)
-$22.14M(-9.3%)
Dec 2002
-$20.26M(-58.0%)
-$3.62M(+7.8%)
-$20.26M(+0.2%)
Sep 2002
-
-$3.93M(+52.3%)
-$20.31M(-5.3%)
Jun 2002
-
-$8.24M(-84.2%)
-$19.28M(-32.9%)
Mar 2002
-
-$4.47M(-22.1%)
-$14.51M(-13.1%)
Dec 2001
-$12.82M(-40.5%)
-$3.66M(-26.0%)
-$12.82M(-2.8%)
Sep 2001
-
-$2.91M(+16.1%)
-$12.48M(-10.7%)
Jun 2001
-
-$3.46M(-24.1%)
-$11.27M(-7.3%)
Mar 2001
-
-$2.79M(+15.9%)
-$10.50M(-15.0%)
Dec 2000
-$9.13M(-20.1%)
-$3.32M(-95.2%)
-$9.13M(-18.8%)
Sep 2000
-
-$1.70M(+36.9%)
-$7.68M(+2.0%)
Jun 2000
-
-$2.69M(-90.1%)
-$7.84M(-6.6%)
Mar 2000
-
-$1.42M(+24.3%)
-$7.36M(+2.7%)
Dec 1999
-$7.60M(-13.4%)
-$1.87M(-1.0%)
-$7.56M(+4.5%)
Sep 1999
-
-$1.86M(+16.1%)
-$7.91M(-25.1%)
Jun 1999
-
-$2.21M(-36.3%)
-$6.32M(+2.4%)
Mar 1999
-
-$1.62M(+27.1%)
-$6.48M(+3.9%)
Dec 1998
-$6.70M(-123.3%)
-$2.23M(-738.3%)
-$6.74M(-20.1%)
Sep 1998
-
-$265.50K(+88.8%)
-$5.61M(+11.6%)
Jun 1998
-
-$2.36M(-25.6%)
-$6.35M(-41.6%)
Mar 1998
-
-$1.88M(-71.0%)
-$4.48M(-49.4%)
Dec 1997
-$3.00M(-87.5%)
-$1.10M(-10.0%)
-$3.00M(-57.9%)
Sep 1997
-
-$1.00M(-100.0%)
-$1.90M(-111.1%)
Jun 1997
-
-$500.00K(-25.0%)
-$900.00K(-125.0%)
Mar 1997
-
-$400.00K
-$400.00K
Dec 1996
-$1.60M
-
-

FAQ

  • What is Sarepta Therapeutics, Inc. annual cash from operations?
  • What is the all-time high annual cash from operations for Sarepta Therapeutics, Inc.?
  • What is Sarepta Therapeutics, Inc. annual cash from operations year-on-year change?
  • What is Sarepta Therapeutics, Inc. quarterly cash from operations?
  • What is the all-time high quarterly cash from operations for Sarepta Therapeutics, Inc.?
  • What is Sarepta Therapeutics, Inc. quarterly cash from operations year-on-year change?
  • What is Sarepta Therapeutics, Inc. TTM cash from operations?
  • What is the all-time high TTM cash from operations for Sarepta Therapeutics, Inc.?
  • What is Sarepta Therapeutics, Inc. TTM cash from operations year-on-year change?

What is Sarepta Therapeutics, Inc. annual cash from operations?

The current annual cash from operations of SRPT is -$205.79M

What is the all-time high annual cash from operations for Sarepta Therapeutics, Inc.?

Sarepta Therapeutics, Inc. all-time high annual cash from operations is $107.47M

What is Sarepta Therapeutics, Inc. annual cash from operations year-on-year change?

Over the past year, SRPT annual cash from operations has changed by +$295.21M (+58.92%)

What is Sarepta Therapeutics, Inc. quarterly cash from operations?

The current quarterly cash from operations of SRPT is -$27.37M

What is the all-time high quarterly cash from operations for Sarepta Therapeutics, Inc.?

Sarepta Therapeutics, Inc. all-time high quarterly cash from operations is $627.79M

What is Sarepta Therapeutics, Inc. quarterly cash from operations year-on-year change?

Over the past year, SRPT quarterly cash from operations has changed by +$43.33M (+61.28%)

What is Sarepta Therapeutics, Inc. TTM cash from operations?

The current TTM cash from operations of SRPT is -$257.43M

What is the all-time high TTM cash from operations for Sarepta Therapeutics, Inc.?

Sarepta Therapeutics, Inc. all-time high TTM cash from operations is $313.22M

What is Sarepta Therapeutics, Inc. TTM cash from operations year-on-year change?

Over the past year, SRPT TTM cash from operations has changed by +$95.06M (+26.97%)
On this page